全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Angela George , Jennifer McLachlan , Nina Tunariu ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:... Agents used include tamoxifen and aromatase inhibitors. Our aim was to evaluate the efficacy of tamoxifen (T) and letrozole (L) in HGOC in clinical practice and investigate factors influencing clinical outcome.
作者:Mariana Tavares Miranda Lima , Kamila Pires de Carvalho , Fernanda Silva Mazzutti ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:The effect of endocrine therapy with tamoxifen (TMX) on weight gain has been reported in the literature, but the outcomes are still controversial. Moreover, previous treatment options, such as chemotherapy (CT), also include body changes. The focus of this study was to verify the...
作者:Qian Wang , Yu Cheng , Yan Wang ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:Although the efficacy of tamoxifen (TAM) for breast cancer has been attributed to inducing cell cycle arrest and apoptosis by inhibiting estrogen receptor (ER) signaling, recent evidence indicates that TAM also possesses ER-independent antitumor activity through an unclear mechan...
作者:Shujie Cheng , Victor Castillo , Matt Welty ...
来源:[J].BMC Complementary and Alternative Medicine(IF 2.082), 2017, Vol.17 (1)Springer
摘要:Tamoxifen (TAM) has been widely used for the treatment of estrogen receptor (ER)-positive breast cancer and its combination with other therapies is being actively investigated as a way to increase efficacy and decrease side effects. Here, we evaluate the therapeutic potential of ...
作者:Meng D , Lei H , Zheng X ...
来源:[J].OncoTargets and Therapy(IF 2.073), 2019, Vol.Volume 12, pp.3919-3931DOAJ
摘要:... Tamoxifen, an antagonist of estrogen receptor-Α (ERΑ), is the first choice for endocrine-dependent breast cancer (ERΑ-positive breast cancer) treatment. However, ERΑ has an important function in the normal physical regulation of estrogen, and current oral administratio...
作者:Nebi Serkan Demirci , Gokmen Umut Erdem , Nil İrem Uçgun ...
来源:[J].Journal of Cancer Research and Therapeutics(IF 0.761), 2019, Vol.15 (3), pp.722-724DOAJ
摘要:Tamoxifen-induced ocular complications including cataracts, keratopathies, retinopathy, impaired visual acuity, ocular irritation, optical neuritis, and retinal vein occlusion are uncommonly reported in the literature. Herein, we report on a premenopausal patient with right-side ...
作者:Huey-En Tzeng , Chih-Hsin Muo , Hsien-Te Chen ...
来源:[J].BMC Musculoskeletal Disorders(IF 1.875), 2015, Vol.16 (1)Springer
摘要:Abstract(#br) Purpose(#br)Bone mineral density changes with tamoxifen treatment have been reported in pre- and post-menopausal women with breast cancer. However, there remains controversy as to whether tamoxifen significantly reduces fracture rates in different age groups. Breast...
作者:Karin Beelen , Mark Opdam , Tesa Severson ...
来源:[J].BMC Cancer(IF 3.333), 2018, Vol.18 (1), pp.1-11DOAJ
摘要:... Whether other proliferation markers, like Cyclin D1, and mitotic count can also be used to identify those estrogen receptor α (ERα) positive breast cancer patients that derive benefit from tamoxifen is not well established. We tested the predictive value of these markers f...
作者:Aamir Ahmad , Kevin R. Ginnebaugh , Shuping Yin ...
来源:[J].BMC Cancer(IF 3.333), 2015, Vol.15 (1)Springer
摘要:Abstract(#br) Background(#br)For breast cancer patients diagnosed with estrogen receptor (ER)-positive tumors, treatment with tamoxifen is the gold standard. A significant number of patients, however, develop resistance to tamoxifen, and management of such tamoxifen-resistant pat...
作者:Hyun-Ah Kim , Sei Hyun Ahn , Seok Jin Nam ...
来源:[J].BMC Cancer(IF 3.333), 2016, Vol.16 (1)Springer
摘要:... However, it is currently unclear if addition of OFS to standard tamoxifen therapy after completion of adjuvant chemotherapy results in a survival benefit. In 2008, the Korean Breast Cancer Society Study Group initiated the ASTRRA randomized phase III trial to evaluate the eff...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×